The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking - Blocking peptide for Anti-Olig2 antibody (ab42453)
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Basic domain helix loop helix protein class B 1
Basic helix loop helix protein class B 1
Class B basic helix loop helix protein 1
Class B basic helix-loop-helix protein 1
class E basic helix loop helix protein 19
Class E basic helix-loop-helix protein 19
Human protein kinase C binding protein RACK17
Oligodendrocyte lineage transcription factor 2
Oligodendrocyte specific bHLH transcription factor 2
Oligodendrocyte transcription factor 2
Protein kinase C binding protein 2
Protein kinase C binding protein RACK17
Protein kinase C-binding protein 2
Protein kinase C-binding protein RACK17
Required for oligodendrocyte and motor neuron specification in the spinal cord, as well as for the development of somatic motor neurons in the hindbrain. Cooperates with OLIG1 to establish the pMN domain of the embryonic neural tube. Antagonist of V2 interneuron and of NKX2-2-induced V3 interneuron development.
Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas highly variable.
Involvement in disease
Note=A chromosomal aberration involving OLIG2 may be a cause of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(14;21)(q11.2;q22) with TCRA.
Contains 1 basic helix-loop-helix (bHLH) domain.
The bHLH is essential for interaction with NKX2-2.
Nucleus. Cytoplasm. The NLS contained in the bHLH domain could be masked in the native form and translocation to the nucleus could be mediated by interaction either with class E bHLH partner protein or with NKX2-2.